Aims: The generation of induced pluripotent stem cells (iPSCs) from peripheral blood mononuclear cells (PBMCs) represents a significant advancement for personalized medicine, disease modeling, and drug discovery. Traditional reprogramming methods using plasmids or viral vectors pose risks, including genomic integration and immune activation. To address these challenges, we introduce a novel mRNA-LNP (lipid nanoparticle) kit designed specifically for efficient and safe reprogramming of PBMCs into iPSCs.
Methodology: Our technology leverages optimized lipid nanoparticles to deliver mRNA encoding essential reprogramming factors, providing a non-viral alternative that eliminates genomic integration while enhancing safety and efficacy. The transient nature of mRNA expression ensures rapid degradation of exogenous genetic material, minimizing oncogenic risks and improving compatibility with clinical applications. The LNPs are engineered for high transfection efficiency and minimal cellular toxicity, enabling effective delivery of reprogramming mRNAs into PBMCs. The kit includes a comprehensive set of components, including purified mRNAs for critical reprogramming factors, pre-formulated LNPs, and specialized reagents to maximize delivery efficiency. The ready-to-use mRNA-LNP formulation can be directly applied to cell cultures, eliminating the need for electroporation or supplemental transfection agents. Using this system, PBMCs can be efficiently reprogrammed into iPSC clones that exhibit hallmark pluripotency markers, trilineage differentiation potential, and stable karyotypic integrity.
Results and conclusion: Compared to traditional methods, our approach eliminates genomic integration risks while achieving comparable or superior reprogramming efficiency. This innovation offers significant potential for advancing translational research, including patient-specific disease modeling, high-throughput drug screening, and regenerative medicine therapies. By combining safety, scalability, and user-friendly protocols, the mRNA-LNP platform sets a new standard for iPSC generation in both research and clinical applications.
